Jan 09th 2013 - Edison Investment Research today published a report on Arrowhead Research Corporation entitled "HBV Data Supports Phase I Move". In summary, the report says:
Arrowhead continues to make good progress in R&D and business development, reporting in recent weeks encouraging preclinical data on the anti-HBV compound ARC 520 and the signing of a licensing deal with Shire for its peptide library. ARC 520 is on track to enter clinical development this year, while data from studies of Arrowhead’s two clinical-stage compounds CALAA-01 (cancer) and Adipotide (obesity) are due in early/mid 2013. These events, plus potential royalties on Cerulean’s CRLX101 in non small-cell lung cancer, have the potential to boost our current $60m valuation, which is solely based on CALAA-01 and Adipotide.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »